CD30-positive T-cell lymphoproliferative disorder (TLPD) encompasses a clinicopathologic spectrum that typically occurs in the oral cavity or occasionally other mucosal sites in the head and neck. This entity was not formally codified in the 2005 WHO classification of Head and Neck Tumours, but has since been added to the current edition. These tumors are analogous to the clinicopathologic spectrum observed in primary cutaneous CD30-positive TLPD. Primarily affecting older adults, these lesions typically present as a mass, often with ulceration [1] . Lesions show sheets of large and atypical neoplastic cells with pleomorphic nuclei, often within a mixed inflammatory background [2] [3] [4] . Neoplastic cells show strong uniform CD30, by definition, express CD4 more often than CD8, frequently express cytotoxic markers and are negative for CD56, ALK and EBV [4] . Recently, rearrangements involving DUSP22 on 6p25.3 have been identified in these lesions, similar to those observed in primary cutaneous TLPD and ALK-negative anaplastic large cell lymphoma [3] . Importantly, most cases of CD30-positive TLPD show complete resolution with local therapy alone [3] [4] [5] .
Introduction
This section applies to hematopoietic and lymphoid neoplasms of the head and neck including the nasal cavity and paranasal sinuses, the nasopharynx, the larynx, the oral cavity and oropharynx, the neck and the salivary glands. While there have been relatively few changes to the Special Issue: World Health Organization Classification Update 
Extranodal NK/T-Cell Lymphoma
Extranodal NK/T-cell lymphoma (ENKTL), nasal type is an extranodal lymphoma with a cytotoxic phenotype, associated with EBV. While this entity was recognized in the 2005 WHO, there have been significant advances in our understanding its underlying pathogenesis. This lymphoma most commonly occurs in the upper aerodigestive tract and is more prevalent among East Asians [6] and the indigenous populations of Mexico and Central and South America [7] . Commonly presenting as nasal obstruction and/or epistaxis, ENKTL frequently shows an angiocentric/ angiodestructive pattern leading to geographic necrosis. The tumor cells express T cell antigens, cytotoxic markers (TIA1, granzyme B or perforin), EBV RNA (EBER) and frequently CD56 [8] (Fig. 1) .
Since the 2005 WHO, our understanding of the molecular pathogenesis of ENKTL has expanded. Several tumor suppressor genes within the commonly deleted region at 6q21-23 have recently been identified including PRDM1, ATG5, AIM1, HACE1, and FOXO3 [9] [10] [11] . In addition to TP53 [12] , DDX3X was recently identified as another commonly mutated tumor suppressor gene [13] . The JAK/ STAT pathway is activated in most cases with frequent genetic alterations of JAK3, STAT3 or PTPRK [14] [15] [16] [17] . While EBV has long been implicated in the pathogenesis of ENKTL, recent studies have shown that EBV infection downregulated host microRNA and that downregulation of MiR-146a [18] and miR-15a promotes cell proliferation and is associated with a poor prognosis [19] . Recent studies have also highlighted the role of quantitative EBV DNA assay in plasma and PET findings in risk stratification [20] .
Extraosseous Plasmacytoma
Extraosseous (extramedullary) plasmacytoma is a massforming proliferation of clonal plasma cells in the absence of underlying plasma cell myeloma, as described in the previous WHO. Important differential diagnoses to exclude include plasmablastic lymphoma and extranodal marginal zone lymphoma with extensive plasmacytic differentiation. These tumors frequently involve the upper respiratory tract and appear as sheets of plasma cells expressing markers of plasmacytic differentiation including CD138, CD38 and MUM1/IRF4 (Fig. 2) . CD79A is variably expressed while CD20 and PAX5 are typically negative. Plasmablastic lymphoma should be considered in the setting of EBV positivity.
Studies have shown similar genetic features between plasma cell myeloma and extraosseous plasmacytoma though differences in IGH translocation partners have been reported [21] .
Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is a diffuse infiltration by intermediate to large-sized B cells with variable cytological features including centroblastic, immunoblastic and anaplastic. DLBCL can occur at any site in the head and neck region. The 2017 Head and Neck WHO does not specifically address the recent advances made in understanding of DLBCL or the separate classifications of DLBCL recognized in the 2016 WHO classification of hematopoietic and lymphoid tumors [22] . In particular, the importance of classifying DLBCL based on cell of origin-activated B-cell (ABC) or germinal center B-cell (GCB)-is widely accepted based on differences in clinical outcome, gene expression, chromosomal alterations and somatic mutations [23, 24] . Recent next-generation sequencing studies have shown that both GCB and ABC DLBCL frequently have inactivating mutations of TP53 and immunosurveillance genes, alterations of epigenetic regulators and oncogenic activation of BCL6. GCB DLBCL have frequent alterations EZH2 and BCL2 translocations similar to follicular lymphoma as well as mutations in the cell motility regulator GNA13. In contrast, ABC DLBCL have frequent mutations in genes activating BCR/ TLR and NFκB pathways (e.g. MYD88, CD79A, CARD11, TNFAIP3). Additional important categories include high grade B-cell lymphoma (HGBL) with rearrangements of MYC and BCL2 and/or BCL6 which is associated with a poor prognosis [17, 19, 25] . Recent studies have also suggested that "double-expressor lymphomas" (i.e. MYC and BCL2) may also have a worse outcome [26] .
EBV + DLBCL, NOS is also recognized as a distinct entity by the 2016 WHO classification of hematopoietic and lymphoid tumors [17, 27, 28] . The "NOS" designation is intended to exclude other entities with neoplastic EBV+ B-cells such as lymphomatoid granulomatosis. However, in the head and neck region, it is important to consider a EBV+ mucocutaneous ulcer, an indolent condition codified as a provisional entity in the 2016 WHO classification of hematopoietic and lymphoid tumors [17] . These lesions frequently appear as circumscribed oral ulcers in immunocompromised or elderly patients and are characterized by a polymorphous infiltrate with atypical large B-cells often resembling Reed-Sternberg cells [29] (Fig. 3) . These ulcers may regress spontaneously or have a relapsing-remitting course, generally requiring only conservative management [24, 30] .
As discussed with follicular lymphoma, it is also important to distinguish DLBLC, NOS from Large B-cell lymphoma with IRF4 rearrangement [17] . This lymphoma which generally occurs in children and young adults most frequently involves the cervical lymph nodes and Waldeyer ring.
Hodgkin Lymphoma
As in the 2005 WHO, classical Hodgkin lymphoma (CHL) is distinct from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). In CHL, the neoplastic cells (mononuclear Hodgkin cells and multi-nucleated Reed-Sternberg cells) have lost expression of many B-cell specific proteins. They are weakly positive for PAX5 but are typically negative (or only weakly positive) for CD20 and CD79A. CD30 is positive in virtually all cases and CD15 in most. The inflammatory background typically consists of T-cells, plasma cells, histiocytes and eosinophils. In NLPHL, the neoplastic cells have lobulated nuclei, retain B-cell antigen expression are rosetted by T follicular helper cells.
The revision acknowledges that there can be overlap between NLPHL and T-cell histiocyte rich large B-cell lymphoma. Approximately 90% of cases demonstrate a rearrangement involving MYC (8q24), most commonly with IGH (14q32) or less frequently to IGK (2p12) or IGL (22q11) [19, 32, 33] . Some controversy exists over whether cases without MYC rearrangements should be classified as BL. These cases are characterized by 11q alterations including proximal gains and telomeric losses [34, 35] . While these cases resemble BL morphologically, immunophenotypically and by gene expression profiling, they show more complex karyotypes, lower MYC expression and may show more cytological pleomorphism. These cases are classified as BL according to the 2017 Head and Neck WHO while the 2016 WHO classification of hematopoietic and lymphoid tumors recognizes a provisional entity designated "Burkitt-like lymphoma with 11q aberration." [17] .
Gene expression profiling studies have shown that endemic and immunodeficiency-associated BL have nearly identical signatures while sporadic cases differ in expression of many genes [36, 37] . Similarly, large-scale sequencing studies have demonstrated differences between endemic and sporadic BL [38, 39] . Endemic cases frequently show both cytomegalovirus and HHV8 infection, expression of EBV lytic genes and recurrent alterations of ARID1A, CCNF and RHOA. By contrast, sporadic cases more frequently show alterations of MYC, ID3, TCF3 and TP53.
Follicular Lymphoma
Follicular lymphoma (FL) is a lymphoma comprised of centrocytes and centroblasts with at least a partially follicular pattern. This category may include both pediatric and adult FL which are now acknowledged to have important clinicopathologic differences. In the head and neck, cervical lymph nodes are the most common site with Waldeyer ring involvement typically representing secondary tonsillar extension from nodal disease [40] . Isolated oropharyngeal FL is rare, most often occurring in children and young adults. In keeping with a germinal center phenotype, cells are positive for CD10 and BCL6. BCL2 is positive in 85-90% of cases.
The revised WHO acknowledges the differences between FL in the tonsil of children and young adults and other cases of FL. FL in this setting typically shows large expansile follicles, positivity for MUM1/IRF4, a high proliferative index and prominent centroblasts or blastoid follicular center cells rather than classic centrocytes [41, 42] . While most FL cases bear the t(14;18) translocation, MUM1/ IRF4-positive FL in children and young adults typically lack the t(14;18) translocation as well as BCL6 and MYC rearrangements and instead carries translocations involving MUM1/IRF4 in approximately 50% of cases [29, 30] . The 2016 WHO classification of hematopoietic and lymphoid tumors separately classifies these cases as "pediatric-type" follicular lymphoma and avoids classifying these cases as conventional grade 3 FL given the generally localized indolent behavior of these cases [17, 29, 30] . In addition, a separate provision entity designated "large B-cell lymphoma with IRF4 rearrangement" has been designated [17, 29, 43] . This entity most frequently occurs in Waldeyer ring and/or cervical lymph nodes and is meant to include lymphomas with follicular, follicular and diffuse, or pure diffuse growth patterns that would otherwise be designated FL grade 3B or DLBCL. This lymphoma is considered more aggressive than other pediatric-type FL, though patients still seem to respond well to treatment [31] . Additional recent findings include the discovery of recurrent mutations of CREBBP, KMT2D and EZH2 occurring early in the pathogenesis of FL [44] [45] [46] .
Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma of small to medium-sized cells. As described in the 2005 WHO, lymphoma cells usually carry a translocation involving CCND1 leading to cyclin D1 overexpression. However, the current WHO recognizes cases of cyclin D1-negative MCL. The head and neck region is the second most common extranodal site with MCL accounting for 2.6% of all Waldeyer ring non-Hodgkin lymphomas [47] [48] [49] . MCL may show a diffuse, vaguely nodular or mantle-zone pattern and is typically positive for IgD, CD20, CD5 and cyclin D1.
The revised WHO points out that SOX11 is useful in identifying rare cyclin D1-negative cases of MCL [50, 51] . While most cases have t(11;14) CCND1-IGH translocations, cyclin-D1 negative cases may have rearrangements of CCND2 or CCND3 [52, 53] . Mutations in many other genes including ATM and TP53 are also common [54] .
T-Lymphoblastic Leukemia/Lymphoma
T-lymphoblastic leukemia/lymphoma (T-LBL/L) is a neoplasm of lymphoblasts committed to T-cell lineage that rarely occurs in the head and neck region [55] . This entity was recognized in the 2005 WHO, but the current edition points out important diagnostic distinctions and recent molecular discoveries. T-LBL/L consists of small to medium-sized cells with fine chromatin, variably conspicuous nucleoli and scant cytoplasm. Lymphoblasts are typically positive for cytoplasmic CD3, TdT, CD7 and CD1a; variably positive for CD10; and either double-positive or double negative for CD4 and CD8. Early T precursor (ETP) acute lymphoblastic leukemia (ALL) is recognized as a provisional entity in the 2016 WHO classification for hematopoietic and lymphoid tumors [56] . This leukemia is characterized by CD7 without CD1a or CD8 and positivity for one or more myeloid/stem cell markers [57] . A high frequency of mutations in myeloid-associated genes is also associated with ETP ALL [58] [59] [60] .
Many cases of T-LBL/L have an abnormal karyotype with frequent translocations involving the T-cell receptor genes [61] . Activation of Notch signaling and loss of CDKN2A are also common [62] .
As the revised WHO points out, it is important to distinguish T-LBL/L from indolent T-lymphoblastic proliferation which is now well recognized as a non-neoplastic entity that can mimic T-LBL/L and frequently involves lymphoid tissue of head and neck [63] . Histologically, these lesions resemble normal thymic cortex without thymic epithelium.
Follicular Dendritic Cell Sarcoma
Follicular dendritic cell (FDC) sarcoma is a rare tumor of nodal and extranodal sites that exhibits phenotypic features similar to FDC. No significant changes have been made in the current classification of this entity. While FDC sarcoma accounts for less than 1% of head and neck tumors, the head and neck is the most common site of involvement for this tumor-most frequently cervical lymph nodes or Waldeyer ring. The tumor displays a pushing border with spindle, ovoid or epithelioid cells, often arranged in fascicular, whorled or storiform growth patterns with admixed small lymphocytes (Fig. 4) 
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) remains largely unchanged in the 2017 WHO. This is an indolent B-cell lymphoma composed of heterogeneous mixture of B-cells including marginal zone (centrocyte-like) cells, monocytoid B-cells, small lymphocytes, plasma cells and scattered immunoblasts and centroblast-like cells [64] (Fig. 5) . The neoplastic cells typically infiltrate the epithelium forming Iymphoepithelial lesions. The head and neck is the second most frequent site of MALT lymphoma, most frequently involving the ocular adnexa, salivary glands, and less commonly Waldeyer ring [65, 66] . MALT lymphoma cells are positive for B-cell antigens and are typically negative for CD5, CD10, BCL6 and cyclin D1. The revised WHO points out that IRTA1, a marker of marginal zone differentiation is positive in the majority of cases [67] . In salivary glands, lymphoepithelial sialadenitis is a precursor lesion for MALT lymphoma [68] . Monoclonal B cells are present in more than half of salivary lesions from Sjögren syndrome patients and the acquisition of mutations such as in TNFAIP3 has been associated with lymphoma development [69] . However, translocations involving MALT1 including t(14;18) (IGH-MALT1), t(11;18) (API2-MALT1) which are commonly observed in MALT lymphomas of other sites including the stomach, are uncommon in head and neck MALT lymphomas [70] . Hepatitis C is another predisposing factor [71] and there is anecdotal evidence of MALT lymphoma arising in the setting of IgG4-related disease [72, 73] .
Plasmablastic Lymphoma
Plasmablastic lymphoma (PBL) is a proliferation of large cells resembling immunoblasts with a plasmacytic immunophenotype. Previously codified as a distinctive form of DLBCL, this neoplasm is now recognized as a completely separate entity. PBL most commonly occurs in the oral cavity but can occur in other extranodal sites including the oropharynx, nasopharynx and sinonasal tract [74, 75] . Lymph nodes are occasionally involved. PBL most frequently occurs in the setting of HIV-related immunosuppression.
PBL is associated with EBV infection and MYC dysregulation with MYC translocations or gains occurring in approximately half of cases [20, 76, 77] .
Langerhans Cell Histiocytosis
Langerhans cell histiocytosis (LCH) is a neoplastic proliferation of Langerhans cells with a peak incidence between 3 and 5 years of age [78] . Similar to other hematolymphoid neoplasms, significant advances in understanding of the pathogenesis of this disease have been made since 2005. Head and neck involvement most commonly affects the skull, orbit, jaw, scalp, periauricular skin, cervical lymph nodes, paranasal sinuses and oral mucosa [79] . Histologically, lesions contain a mixture of inflammatory cells and neoplastic cells with folded or grooved nuclei [80] . These cells express S100, CD1a and CD207 (langerin).
LCH is now known to result from activation of the mitogen activated protein kinase (MAPK) pathway resulting from BRAF V600E mutations in approximately half of cases [81] and MAP2K1 mutations in approximately one quarter [82] .
Extramedullary Myeloid Sarcoma
Extramedullary myeloid sarcoma is mass consisting of myeloid blasts occurring outside of the bone marrow. There have not been significant changes in description of this entity since the 2005 WHO. This disease can occur de novo or be associated with acute myeloid leukemia or another myeloid neoplasm [83] . The oral cavity is the most common site, but any head and neck site may be involved [84] . A variety of chromosomal aberrations have been reported including monosomy 7, trisomy 8, inv (16) and t(8;21)-particularly in pediatric patients [28] . NPM1 mutations are also found in 16% of cases [85] .
